ARSENOPLATINS VS COMBINATION OF PLATINUM DRUGS AND ARSENIC TRIOXIDE
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The serendipitous discovery of cisplatin and its approval as an anticancer agent by the FDA in 1978
marked the beginning of using metal complexes as anticancer drugs. Cisplatin is used to treat ovarian,
bladder, testicular, and other cancers. Two other drugs, carboplatin (used for the treatment of advanced
ovarian cancer) and oxaliplatin (used for the treatment of colorectal cancer and stage III colon cancer)
were approved in 1989 and 1996, respectively. All three platinum drugs have two nitrogen donors in cis
position. The geometrical isomer of cisplatin, transplatin, did not show efficacy in tumors, and for an
extended period scientist believed that trans(N) platinum compounds were not effective against tumors.
The main obstacle in using the FDA approved platinum drugs is intrinsic and acquired resistance, and an
intensive search for structurally different platinum drugs is underway. Recently, trans(N)-platinum
compounds emerged as anticancer agents that are active against cisplatin-resistant cell lines.
Arsenic trioxide is another inorganic drug that is FDA approved for the treatment of acute promyelocytic
leukemia (APL). More than 90% of APL patients were cured with this drug. The success of arsenic
trioxide in leukemia was not repeated in solid tumors due to the arsenic trioxide rapid renal clearance. A
synergy effect exists between arsenic trioxide and cisplatin in several cancer cell lines. Inspired by these
results, we synthesized arsenoplatins, small molecular compounds that combine platinum and arsenic
pharmacophores in the form of one entity. NCI-60 screening of human tumor cell lines has shown that
the first representative of this class of agents, arsenoplatin-1, is more potent than arsenic trioxide in all
nine indications tested. ICP-MS experiments on AP-1 DNA adducts isolated from triple negative MDAMB-231 cancer cell line treated by AP-1 confirmed the ability of arsenoplatin-1 to bind to DNA. After
longer incubation time, we found that the Pt/As ratio in AP-1-DNA samples increases. This implies that
the platinum-arsenic bond breaks in the cellular milieu and arsenic moiety releases from the AP-1-DNA
adducts. Based on our results, arsenoplatin-1 acts as a dual pharmacophore anticancer agent which can
deliver platinum and arsenic species to solid tumors. Arsenoplatin-1 also satisfies the Lipinski rule of five
used to predict not only the permeability through the cell membrane, but also the overall drug-likeness.
Syntheses of conjugates of arsenoplatins with proteins and peptides for targeted delivery is underway.

